Vadim Alexandre gives an overview of e-Therapeutics and explains the reasons for their Fundraise

e-therapeutics plc #ETX announces the successful completion of a Placing, Subscription and Retail Offer via PrimaryBid conditionally raising gross proceeds of £22.5 million for the Company. In total, 93,750,000 new Ordinary Shares will be issued pursuant to the Fundraise at the Placing Price of 24 pence per new Ordinary Share.

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

 

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small subsets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

 

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.